幕上单侧去骨瓣减压术在不同患者亚组中的适应证与科学依据:范围综述
本范围综述检索Medline/PubMed数据库自建库至今,评估7种幕上单侧去骨瓣减压术(DC)适应证的证据水平与质量。结果发现,高质量证据仅支持重型创伤性脑损伤和恶性大脑中动脉梗死;对急性硬膜下血肿、恶性脑膜脑炎、恶性脑静脉血栓形成及高度选择的动脉瘤性蛛网膜下腔出血有部分科学依据;对脑出血和颅内肿瘤证据不足。
要点
- 两项随机试验(1b级)报告单侧DC可能有效、双额DC疗效有限,用于创伤 setting。
- 五项系统综述Meta分析(2a级)支持DC用于年轻重型颅脑损伤伴急性硬膜下血肿者。
- 三项随机试验(1b级)和两项Meta分析(1a和3a级)支持DC用于恶性缺血性卒中。
核心结论
- 目前有一定科学依据支持临床医生对选择的严重创伤性脑损伤、急性硬膜下血肿、恶性缺血性卒中、恶性脑膜脑炎、恶性脑静脉血栓形成及高度选择的动脉瘤性蛛网膜下腔出血病例行DC决策。
研究设计与样本
- 范围综述,检索Medline/PubMed数据库自建库至今,聚焦7种可能的DC适应证。
- 纳入研究证据水平采用牛津大学证据水平量表评估,质量采用纽卡斯尔-渥太华量表(队列研究系统综述)和Cochrane偏倚风险工具(随机对照试验)评估。
主要发现
- 两项随机试验(1b级)报告单侧DC可能有效,双额DC疗效有限,用于创伤 setting。
- 五项系统综述Meta分析(2a级)支持DC用于年轻严重损伤伴急性硬膜下血肿、可能为术中脑肿胀负责的患者。
- 一项随机对照试验(1b级)显示DC与开颅术对术中脑肿胀中性的急性硬膜下血肿疗效相当。
- 三项随机对照试验(1b级)和两项Meta分析(1a和3a级)支持DC对恶性缺血性卒中的疗效。
- 一项系统综述(3a级)支持DC对恶性脑膜脑炎的疗效;一项系统综述Meta分析(3a级)支持DC对恶性脑静脉血栓形成的疗效。
关键数值与推荐
- 两项随机试验(1b级)报告单侧DC可能有效、双额DC疗效有限,用于创伤 setting。
- 五项系统综述Meta分析(2a级)支持DC用于年轻严重损伤伴急性硬膜下血肿、可能为术中脑肿胀负责的患者。
- 一项随机对照试验(1b级)显示DC与开颅术对术中脑肿胀中性的急性硬膜下血肿疗效相当。
- 三项随机对照试验(1b级)和两项Meta分析(1a和3a级)支持DC对恶性缺血性卒中的疗效。
- 一项系统综述(3a级)支持DC对恶性脑膜脑炎的疗效;一项系统综述Meta分析(3a级)支持DC对恶性脑静脉血栓形成的疗效。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Even though supratentorial unilateral decompressive craniectomy (DC) has become the gold standard neurosurgical procedure aiming to provide long term relief of intractable intracranial hypertension, its indication has only been validated by high-quality evidence for traumatic brain injury and malignant middle cerebral artery infarction. This scoping review aims to summarize the available evidence regarding DC for these two recognized indications, but also for less validated indications that we may encounter in our daily clinical practice. MATERIALS AND METHODS: A scoping review was conducted on Medline / Pubmed database from inception to present time looking for articles focused on 7 possible indications for DC indications. Studies' level of evidence was assessed using Oxford University level of evidence scale. Studies' quality was assessed using Newcastle-Ottawa scale for systematic reviews of cohort studies and Cochrane Risk of Bias Tool for randomized controlled trials. RESULTS: Two randomized trials (level 1b) reported the possible efficacy of unilateral DC and the mitigated efficiency of bifrontal DC in the trauma setting. Five systematic reviews meta-analyses (level 2a) supported DC for severely injured young patients with acute subdural hematoma probably responsible for intraoperative brain swelling, while one randomized controlled trial (level 1b) showed comparable efficacy of DC and craniotomy for ASH with intraoperative neutral brain swelling. Three randomized controlled trials (level 1b) and two meta-analyses (level 1a and 3a) supported DC efficacy for malignant ischemic stroke. One systematic review (level 3a) supported DC efficacy for malignant meningoencephalitis. One systematic review meta-analysis (level 3a) supported DC efficacy for malignant cerebral venous thrombosis. The mitigated results of one randomized trial (level 1b) did not allow to conclude for DC efficacy for intracerebral hemorrhage. One systematic review (level 3a) reported the possible efficacy of primary DC and the mitigated efficacy of secondary DC for aneurysmal subarachnoid hemorrhage. Too weak evidence (level 4) precluded from drawing any conclusion for DC efficacy for intracranial tumors. CONCLUSION: To date, there is some scientific background to support clinicians in the decision making for DC for selected cases of severe traumatic brain injury, acute subdural hematoma, malignant ischemic stroke, malignant meningoencephalitis, malignant cerebral venous thrombosis, and highly selected cases of aneurysmal subarachnoid hemorrhage.
引用
- Beucler N. Indications and scientific support for supratentorial unilateral decompressive craniectomy for different subgroups of patients: A scoping review. Acta Neurochir (Wien). 2024. PMID: 39340636. doi:10.1007/s00701-024-06277-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。